HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

被引：6
|
作者：
Florence, E. [1 ]
De Wit, S. [2 ]
Castagna, A. [3 ]
Ribera, E. [4 ]
Hill, A. [5 ]
Vanaken, H. [6 ]
van Delft, Y. [7 ]
Marks, S. [7 ]
机构：
[1] Prince Leopold Inst Trop Med, Antwerp, Belgium
[2] St Pierre Univ Hosp, Brussels, Belgium
[3] Hosp San Raffaele, IRCCS, Dept Infect Dis, I-20132 Milan, Italy
[4] Hop Vall dHebron, Barcelona, Spain
[5] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[6] Tibotec BVBA, Mechelen, Belgium
[7] Janssen Cilag BV, Tilburg, Netherlands
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2010年 / 21卷 / 03期
关键词：
INFECTION;
D O I：
10.1258/ijsa.2009.009425
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：224 / 225
页数：2
相关论文
共 33 条
  • [1] Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Barrail-Tran, Aurelie
    Yazdanpanah, Yazdan
    Goldwirt, Lauriane
    Chene, Genevieve
    Colin, Celine
    Piketty, Christophe
    Bollens, Diane
    Katlama, Christine
    Descamps, Diane
    Molina, Jean-Michel
    Fagard, Catherine
    Taburet, Anne-Marie
    AIDS, 2010, 24 (16) : 2572 - 2574
  • [2] Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'
    Cattaneo, Dario
    Gervasoni, Cristina
    AIDS, 2011, 25 (07) : 1012 - 1013
  • [3] Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States
    Towner, William
    Lalezari, Jacob
    Sension, Michael G.
    Wohlfeiler, Michael
    Gathe, Joseph
    Appelbaum, Jonathan S.
    Bellman, Paul
    Gottlieb, Michael S.
    Ryan, Robert
    Nijs, Steven
    Hoogstoel, Annemie
    Van Solingen-Ristea, Rodica
    Witek, James
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (05) : 614 - 618
  • [4] Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme
    Loutfy, Mona
    Ribera, Esteban
    Florence, Eric
    De Wit, Stephane
    Castagna, Antonella
    Ryan, Robert
    Hill, Andrew
    Vanaken, Hilde
    van Delft, Yvonne
    Marks, Stephan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (06) : 1341 - 1344
  • [5] Reply to comment on 'pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'
    Barrail-Tran, Aurelie
    Yazdanpanah, Yazdan
    Goldwirt, Lauriane
    Chene, Genevieve
    Colin, Celine
    Piketty, Christophe
    Bollens, Diane
    Katlama, Christine
    Descamps, Diane
    Molina, Jean-Michel
    Fagard, Catherine
    Taburet, Anne-Marie
    AIDS, 2011, 25 (07) : 1011 - 1012
  • [6] Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients
    Hull, Mark W.
    Montaner, Julio S. G.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1433 - 1437
  • [7] Effect of Efavirenz, Nevirapine, Etravirine, and Raltegravir Administration on the Pharmacokinetics of Ritonavir-Boosted Darunavir in a Population of HIV-Infected Patients
    Dailly, Eric
    Allavena, Clotilde
    Bouquie, Regis
    Deslandes, Guillaume
    Raffi, Francois
    Jolliet, Pascale
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (01) : 42 - 46
  • [8] Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection
    Imaz, Arkaitz
    Villar del Saz, Sara
    Angels Ribas, M.
    Curran, Adrian
    Caballero, Estrella
    Falco, Vicenc
    Crespo, Manel
    Ocana, Inma
    Diaz, Marjorie
    Ruiz de Gopegui, Enrique
    Riera, Melcior
    Ribera, Esteban
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (03) : 382 - 386
  • [9] Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients
    ter Heine, Rob
    Mulder, Jan Willem
    van Gorp, Eric C. M.
    Wagenaar, Jiri F. P.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 475 - 483
  • [10] High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
    Yazdanpanah, Y.
    Fagard, C.
    Descamps, D.
    Taburet, A. M.
    Colin, C.
    Roquebert, B.
    Katlama, C.
    Pialoux, G.
    Jacomet, C.
    Piketty, C.
    Bollens, D.
    Molina, J. M.
    Chene, G.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1441 - 1449
1234